Approval · Notice of Compliance 30526 · 2023
COVIFENZ: Notice of Compliance 30526
Issued March 30, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30526
- Date
- March 30, 2023
- Company
- Medicago IncQuebec, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expansion of indication: Active immunization to prevent to coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COVIFENZ | Not yet assigned | — |
Medicinal ingredients
- VIRUS-LIKE PARTICLES (VLP) OF SARS-COV-2 SPIKE PROTEIN 3.75 MCG per 0.5ML